Bioventus Inc.BVS

Bioventus Inc. Revenue Disclosure

10-KFiled Mar 11, 20251 min read
Revenue recognition
The Company attributes net sales to external customers to the U.S. and to all foreign countries based on the legal entity from which the sale originated. Refer to Note 2. Significant accounting policies for further information regarding revenue recognition. As previously discussed in Note 1. Organization, SonicOne revenue was reclassified from Restorative Therapies to Surgical Solutions on a retrospective basis as its capabilities to remove devitalized or necrotic tissue and fiber deposits more closely align with Surgical Solutions’ soft tissue management. SonicOne revenue reclassified for the year ended December 31, 2023 and 2022 totaled $6,833 and $6,845, respectively, for the U.S. reporting segment and $299 and $281, respectively, for the International reporting segment. The Company had product sales to one customer totaling $59,742 primarily in the U.S. reporting segment during the year ended December 31, 2024, representing 10.4% of total net sales. There were no customers representing 10% or more of net sales during the years ended December 31, 2023 and 2022.
The following table presents the Company’s net sales disaggregated by major products within each segment as follows for the years ended December 31:
202420232022
U.S.
Pain Treatments
$234,936 $197,954 $194,830 
Surgical Solutions167,706 141,888 133,052 
Restorative Therapies104,167 110,018 127,369 
Total U.S. net sales506,809 449,860 455,251 
International
Pain Treatments
26,353 22,847 21,495 
Surgical Solutions21,549 19,715 15,232 
Restorative Therapies18,569 19,923 20,139 
Total International net sales66,471 62,485 56,866 
Total net sales$573,280 $512,345 $512,117 

About Revenue Disclosures

Revenue disclosures under ASC 606 explain how a company identifies performance obligations, allocates transaction prices, and determines when revenue is recognized. This section is essential for understanding whether reported revenue reflects genuine economic activity or aggressive accounting choices. Analysts examine the mix of point-in-time versus over-time recognition, which directly affects revenue timing and comparability.

Key signals: rising contract liabilities (deferred revenue) suggest strong future revenue visibility, while declining contract assets may indicate slowing project milestones. Watch for variable consideration estimates — rebates, returns, and performance bonuses that require management judgment. Significant changes in disaggregated revenue by geography or product line can reveal shifting business mix before it appears in headline numbers. Compare revenue growth against contract liability growth to assess sustainability, and scrutinize any changes in the timing of recognition that coincide with earnings pressure.

Other Available Disclosures

Income TaxesEarnings Per ShareFair ValuePP&ESegmentsDebtCommitmentsNew Standards